Send to

Choose Destination
J Clin Oncol. 2011 Feb 10;29(5):532-43. doi: 10.1200/JCO.2010.30.1382. Epub 2011 Jan 10.

Modern therapy of acute lymphoblastic leukemia.

Author information

Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy.


Although acute lymphoblastic leukemia is curable in one third of adult patients, results vary greatly on account of different clinical, immunologic, and cytogenetic/genetic characteristics. These data, along with the kinetics of response to early treatment, help establish the individual risk class with considerable accuracy, and support risk-specific treatments that should warrant optimal results with as little as possible nonrelapse mortality. Modern first-line therapy consists of standard- and high-dose chemotherapy (increasingly inspired to pediatric principles), hematopoietic stem-cell transplantation, and new targeted therapy, all integrated with the analysis of prognostic factors and the study of subclinical residual disease for key therapeutic decisions. These changes are improving long-term outcome, which in ongoing studies is expected close to 50% or greater.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center